<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04790318</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU R 48/2020/2021</org_study_id>
    <nct_id>NCT04790318</nct_id>
  </id_info>
  <brief_title>Trans-incisional Quadratus Lumborum Block Versus Caudal Analgesia in Pediatric Open Renal Surgeries.</brief_title>
  <official_title>Trans-incisional Quadratus Lumborum Block Versus Caudal Analgesia in Pediatric Open Renal Surgeries, a Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is scare literature about the usage of QLB in pediatric population, particularly the&#xD;
      trans-incisional approach. Hence, the purpose of this study is to compare the postoperative&#xD;
      analgesic efficacy of ultrasound-guided caudal epidural block versus ultrasound-guided QLB&#xD;
      (trans-incisional) in combination with general anesthesia in pediatric patients undergoing&#xD;
      elective open renal surgeries regarding pain scores, total analgesic consumption, and adverse&#xD;
      effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First time to analgesic requirement</measure>
    <time_frame>1st 24 hour</time_frame>
    <description>Ketorolac is an IV NSAID that has been shown to have similar efficacy to morphine . Ketorolac will be dosed at 0.5 mg/kg every 6-8 hours for the 1st 24 h postoperatively as an analgesic after request.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total analgesic consumption</measure>
    <time_frame>1st 24 hour</time_frame>
    <description>Ketorolac will be dosed at 0.5 mg/kg every 6-8 hours for the 1st 24 h postoperatively as an analgesic after request.Total ketorolac consumption per 24 h will be calculated .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Face, leg, activity, cry, consolability scale (FLACC)</measure>
    <time_frame>1st 24 hours postoperatively</time_frame>
    <description>Pain scores will be evaluated by a blinded observer anesthesiologist at the time of arrival in the PACU and 10, 20, and 30 min and 1, 2, 4, 6, 12, and 24 h thereafter using the face, leg, activity, cry, consolability scale (FLACC) (ranging from 0-10, where 0 = no pain, 10 = worst pain).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>General Anesthesia +TiQLB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive combined general anesthesia and quadratus lumborum block (trans-incisional) with 0.5 mL/kg of bupivacaine 0.2 %. with maximum volume limited to 20 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>General Anesthesia+ Caudal block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive combined general anesthesia and caudal analgesia (just after wound closure) with 1.25 mL/kg of bupivacaine 0.2 % (three parts 0.25 % bupivacaine to one part saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trans-incisional Quadratus lumborum block</intervention_name>
    <description>patients will receive combined general anesthesia and quadratus lumborum block (trans-incisional) with 0.5 mL/kg of bupivacaine 0.2 %. with maximum volume was limited to 20 ml</description>
    <arm_group_label>General Anesthesia +TiQLB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Caudal block</intervention_name>
    <description>patients will receive combined general anesthesia and caudal analgesia (just after wound closure) with 1.25 mL/kg of bupivacaine 0.2 % (three parts 0.25 % bupivacaine to one part saline.</description>
    <arm_group_label>General Anesthesia+ Caudal block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients who will be scheduled for indicated open pediatric renal surgery in the&#xD;
             lateral decubitus position (nephrectomy, partial nephrectomy, pyeloplasty and&#xD;
             nephrolithotomy for complex renal stones).&#xD;
&#xD;
          2. physical status American Society of Anesthesiologists (ASA) I or II.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. - patients whose guardians refuse to participate.&#xD;
&#xD;
          2. -ASA physical status &gt;II. 3-patients who have contraindications to regional analgesic&#xD;
             procedures. 4-patients who have major illnesses (e.g., cardiac, respiratory, renal,&#xD;
             hepatic or neurological).&#xD;
&#xD;
        5-spine or chest wall deformity. 6-History of previous renal surgeries. 7-Coagulation&#xD;
        abnormalities. 8-Infection at the injection site. 9-An allergy or contraindications to the&#xD;
        drugs used in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Amin Mohammed Alansary Amin Ahmed Helwa</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

